A prospective Real-Life Multicenter Study of Tildrakizumab 200 mg in Patients with Moderate-Severe Psoriasis: Who is the Ideal Patient?
Di Brizzi EV, Caccavale S, Di Caprio R, Cusano F, De Pasquale R, Falcomatà V, Foti C, Giofrè C, Gubinelli E, Mazzocchetti G, Nicolini M, Palazzo G, Pescitelli L, Puca RV, Sarno O, Balato A.
Di Brizzi EV, et al. Among authors: pescitelli l.
Dermatol Pract Concept. 2024 Oct 30;14(4):e2024284. doi: 10.5826/dpc.1404a284.
Dermatol Pract Concept. 2024.
PMID: 39453881
Free PMC article.